Imaging Quality and Potential Clinical Relevance of Phase Contrast Mammography In-vivo: a Single-center, Prospective Study

NCT ID: NCT06489665

Last Updated: 2025-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-17

Study Completion Date

2030-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Conventional mammography, breast sonography and breast MRI have specific weaknesses. In particular, mammography has a low sensitivity for the detection of mammary carcinoma in patients with a dense breast. Phase contrast mammography could help to overcome some of these limitations. Observational study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Category C2 Medicine product without CE label.

Objective(s):

Phase 0: Imaging of mastectomy and breast biopsy samples to validate the image quality and radiation dose. Phase 1: Determination of accurate radiation dose in vivo; dose exposure should remain within the range specified in the investigational brochure. Evaluation of cohort size for phase 2. Phase 2: Assessment of the diagnostic performance of phase contrast mammography compared to conventional digital mammography.

Ouctomes: Sensitivity and specificity of phase contrast mammography compared to conventional digital mammography.

Measurements and procedures:

Phase 0: Phase contrast mammography of the mastectomy, tumorectomy or breast biopsy samples is performed after breast surgery in addition to the standard clinical procedures Phase 1: Phase contrast mammography is performed before the operation in case of known breast carcinoma in addition to the standard clinical procedures Phase 2: Phase contrast mammography is performed directly in the clinical routine. The result is compared with the result of the conventional digital mammography and the ultrasound examination.

Number of Participants with Rationale:

Phase 0: expected to be 30 Phase 1: expected to be 20 Phase 2: expected to be 300 (correct number will be defined according to Phase 1)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Microcalcification Image

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mammography finding

Describes the mammography finding in patients prior breast surgery

Experimental Intervention

Intervention Type DIAGNOSTIC_TEST

Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device

Bellona

Describes the finding in the breast tissue samples

Experimental Intervention

Intervention Type DIAGNOSTIC_TEST

Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental Intervention

Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

control intervention

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \>18 years
* Mastectomy, tumorectomy or biopsy planned
* Informed consent of the patient


* \>18 years
* BI-RADS 5 (highly suggestive of malignancy at ultrasound or mammography) or 6 (known biopsy proven malignancy);
* Scheduled for mastectomy or breast conserving surgery with radiotherapy.
* Informed consent of the patient


* \>40 years
* undergoing mammography for screening or diagnostic purpose.
* Informed consent of the patient

Exclusion Criteria

* Breast implants. The women will be asked, if they have a breast-implant.
* Inability to understand the study procedure due to cognitive or linguistic deficits.


* Pregnancy
* Breast-feeding.
* Re-staging after neoadjuvant chemotherapy. Patients who participated in prior research projects with ionizing radiation in the past 12 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland

OTHER

Sponsor Role collaborator

GratXray AG

UNKNOWN

Sponsor Role collaborator

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas Frau, Prof

Role: PRINCIPAL_INVESTIGATOR

University Hospital Zurich, DIR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Zurich - Diagnostic Radiology

Zurich, Canton of Zurich, Switzerland

Site Status RECRUITING

University of Zurich

Zurich, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Thomas Frauenfelder, Prof

Role: CONTACT

+41 44 255 93 83

Judith Jehle

Role: CONTACT

0763257051

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Thomas Frauenfelder, PD MD

Role: primary

0041442551111

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-00200

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Using Diagnostic Tools to Stage Breast Cancer
NCT00367666 ACTIVE_NOT_RECRUITING NA